• Home
  • Congress & Events
  • ASRS 2024
  • Extended Interval Treatment Outcomes and the Potential for Q20W Dosing for the Treatment of Neovascular Age-Related Macular Degeneration With Faricimab▼: a Post Hoc Analysis of the TENAYA/LUCERNE Trials

ASRS 2024

Jul 17 - Jul 20, 2024 | Stockholm, Sweden

Share this page

Close Tooltip
Copy Link Tooltip

Copy page URL

Extended Interval Treatment Outcomes and the Potential for Q20W Dosing for the Treatment of Neovascular Age-Related Macular Degeneration With Faricimab▼: a Post Hoc Analysis of the TENAYA/LUCERNE Trials

Authors Patel P, Koh A, Singer M, Hill L, Kotecha A, Margaron P

Published date20 July, 2024

This presentation summarizes a post hoc analysis of the impact of maintaining extended faricimab▼ treatment intervals (≥ Q12W) on visual and anatomical outcomes in the TENAYA and LUCERNE trials and evaluates how many patients could have been extended to Q20W dosing had the trials allowed.

Download Current View

Welcome to Medically

The Roche Science Hub

This website is a non-promotional global resource intended to facilitate transparent scientific exchange regarding developments in medical research, diagnostics, and disease management. It is intended for healthcare professionals.

Not a healthcare professional? Browse:

This global website is intended for healthcare professionals outside the UK, US, Canada and Australia. The content on this website may include scientific information about experimental or investigational compounds, indications and services that are not approved or valid in your jurisdiction. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website. Information available on this website does not constitute professional medical advice, and Roche and Genentech accept no responsibility for access to or use of the same.

You are Leaving Medically

By following this link, you are leaving Roche Website and entering a site that is not owned or controlled by Roche. Roche does not take any responsibility for acces to or use of this website, nor for any content therein.

You are Leaving the Global Medically Site

By following this link, you are being redirected to another Roche page.